MOLECULAR MECHANISMS UNDERLYING HEPARIN-INDUCED LEUKOCYTOSIS

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 多年来临床上已证实，肝素在患者接受药物后可诱导白细胞增多，提示临床剂量的肝素可短暂调节患者的白细胞运输。然而，迄今为止，肝素治疗如何导致患者的白细胞增多仍然是未知的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. It has been manifested clinically for many years that heparin induces leukocytosis in patients after receiving the drug, suggesting that heparin at clinical dosage transiently modulates leukocyte trafficking in patients. However, to date, it still remains unknown how heparin treatment leads to the leukocytosis in patients.